Michael Kamm

Approach to Dietary Restriction in Irritable Bowel Syndrome.

Jessica E Peters, Michael A Kamm, Chamara Basnayake

Journal article  |  2021  |  Clin Gastroenterol Hepatol

Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia

SW Lo, W Connell, MA Kamm, M Lust, EK Wright

Journal article  |  2021  |  ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Endoscopic Prediction of Crohn's Disease Postoperative Recurrence.

Peter De Cruz, Amy L Hamilton, Kathryn J Burrell, Alexandra Gorelik, Danny Liew, Michael A Kamm

Journal article  |  2021  |  Inflamm Bowel Dis

BACKGROUND: The presence and severity of endoscopic recurrence after Crohn's disease intestinal resection predicts subsequent dise..

Fecal microbiota transplantation therapy in Crohn's disease: Systematic review

Sasha R Fehily, Chamara Basnayake, Emily K Wright, Michael A Kamm

Journal article  |  2021  |  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

BACKGROUND: The gastrointestinal microbiota is the key antigenic drive in the inflammatory bowel diseases. Randomized controlled t..

Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic

Rushab Shah, Emily Wright, George Tambakis, Jacinta Holmes, Alexander Thompson, William Connell, Mark Lust, Ola Niewiadomski, Michael Kamm, Chamara Basnayake, John Ding

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

BACKGROUND: Advances in inflammatory bowel disease (IBD) monitoring, greater number of available treatments and a shift towards ti..

Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease

Vandita Y Mattoo, Chamara Basnayake, William R Connell, Nik Ding, Michael A Kamm, Mark Lust, Ola Niewiadomski, Alexander Thompson, Emily K Wright

Journal article  |  2021  |  ALIMENTARY PHARMACOLOGY & THERAPEUTICS

BACKGROUND: Loss of response to anti-TNF agents is a common clinical problem. Dose escalation may be effective for reestablishing ..

Novel strain-level resolution of Crohn's disease mucosa-associated microbiota via an ex vivo combination of microbe culture and metagenomic sequencing

JJ Teh, EM Berendsen, EC Hoedt, S Kang, J Zhang, F Zhang, Q Liu, AL Hamilton, A Wilson-O'Brien, J Ching, JJY Sung, J Yu, SC Ng, MA Kamm, M Morrison

Journal article  |  2021  |  ISME JOURNAL

The mucosa-associated microbiota is widely recognized as a potential trigger for Crohn's disease pathophysiology but remains large..

459 CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. THE STRIDENT RANDOMISED CONTROLLED TRIAL.

Julien D Schulberg, Emily K Wright, Bronte A Holt, Tom Sutherland, Alyson Ross, Amy L Hamilton, Sara Vogrin, Ashley M Miller, William Connell, Mark Lust, Nik S Ding, Gregory T Moore, Sally J Bell, Edward Shelton, Britt Christensen, Peter De Cruz, Yuwei J Rong, Michael A Kamm

Journal article  |  2021  |  Gastroenterology

Sa533 NOVEL CHARACTERIZATION OF THE SECRETOMES OF CROHN'S DISEASE MUCOSA-ASSOCIATED MICROBIOTA, AND THEIR MODULATION OF INFLAMMATION THROUGH NF-κB SIGNALLING. THE ENIGMA STUDY.

Jing Jie Teh, Seungha Kang, Lauren F Schooth, Jeimy Johana Jimenez Loayza, Jingwan Zhang, Fen Zhang, Qin Liu, Amy L Hamilton, Amy Wilson-O'Brien, Jessica Y Ching, Joseph J Sung, Jun Yu, Siew C Ng, Michael A Kamm, Mark Morrison

Journal article  |  2021  |  Gastroenterology

604 FOOD ADDITIVES ENHANCE PRO-INFLAMMATORY BACTERIAL GROWTH IN CROHN'S DISEASE MUCOSA-ASSOCIATED MICROBIOTA. THE ENIGMA STUDY.

Seungha Kang, Ashley de Klerk, Ebony Noon, Jing Jie Teh, Jingwan Zhang, Fen Zhang, Qin Liu, Amy L Hamilton, Amy Wilson-O'Brien, Gina L Trakman, Winnie Y Lin, Jessica Y Ching, Joseph J Sung, Jun Yu, Siew C Ng, Michael A Kamm, Mark Morrison

Journal article  |  2021  |  Gastroenterology